MEXITIL
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
Dec 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 6h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEXITIL is an oral small-molecule antiarrhythmic agent approved in 1985 by Boehringer Ingelheim. The drug is indicated for cardiac arrhythmia management via oral capsule administration. Mechanism of action and specific pharmacologic class are not currently documented in available data.
LOE Approaching
As LOE approaches, brand team focus will shift toward defensive strategies, lifecycle management, and preparation for generic erosion; team size likely stable to declining.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MEXITIL offers limited growth trajectory given the LOE-approaching lifecycle stage; roles are primarily defensive and focused on protecting market position during generic erosion. Career advancement may be constrained, but positions offer stability and expertise in mature product management and antiarrhythmic therapy.
Brand ManagerMedical Science Liaison
Worked on MEXITIL at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.